Search

Displaying results 3011 - 3020 of 9322 in total
  1. Drug

    Isoflavone

    go.drugbank.com/drugs/DB12007
    ApprovedInvestigationalWithdrawn

    The main soy isoflavones are mostly present in glycosylated forms and include [DB01645], [DB13182], and glycitein, which accounts for approximately 50%, 40%, and 10%, respectively, of the total soybean … While existing data are consistent or inadequate in supporting most of the suggested health benefits of consuming soy proteins and isoflavones [A33099], the trials investigating isoflavone as a potential

  2. Drug

    Bebtelovimab

    go.drugbank.com/drugs/DB16755
    ApprovedWithdrawn

    in the US. … in the treatment of COVID-19 caused by the Omicron variant.

  3. Drug

    Netupitant

    go.drugbank.com/drugs/DB09048
    ApprovedInvestigational

    The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo. … Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy

  4. Drug

    Mexiletine

    go.drugbank.com/drugs/DB00379
    ApprovedInvestigational

    Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.

  5. Drug

    Ceftaroline fosamil

    go.drugbank.com/drugs/DB06590
    ApprovedInvestigational

    Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections

  6. Drug

    Basiliximab

    go.drugbank.com/drugs/DB00074
    ApprovedInvestigational

    known as CD25 antigen) on the surface of activated T-lymphocytes. … and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.

    Products: SIMULECT 20 MG İNFÜZYON VEYA ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET
  7. Drug

    Rifaximin

    go.drugbank.com/drugs/DB01220
    ApprovedInvestigational

    Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered … It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.

  8. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    [L34304] The FDA later announced the final withdrawal of the approval of infigratinib for this indication on May 16, 2024: This decision was based on the sponsor's request due to clinical trial recruitment … [A235174] Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy.

  9. Drug

    Dacarbazine

    go.drugbank.com/drugs/DB00851
    ApprovedInvestigational

    (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.

    Products: DAKARBAZ 100 MG IV/IA İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ VE ÇÖZÜCÜ, DAKARBAZ 200 MG IV/IA İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ VE ÇÖZÜCÜ
  10. Drug

    Ditiocarb zinc

    go.drugbank.com/drugs/DB14193
    Approved

    Sensitivity to ditiocarb zinc may be identified with a clinical patch test.